Last reviewed · How we verify
Lutetium Lu 177-Edotreotide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lutetium Lu 177-Edotreotide (Lutetium Lu 177-Edotreotide) — ITM Solucin GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lutetium Lu 177-Edotreotide TARGET | Lutetium Lu 177-Edotreotide | ITM Solucin GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lutetium Lu 177-Edotreotide CI watch — RSS
- Lutetium Lu 177-Edotreotide CI watch — Atom
- Lutetium Lu 177-Edotreotide CI watch — JSON
- Lutetium Lu 177-Edotreotide alone — RSS
Cite this brief
Drug Landscape (2026). Lutetium Lu 177-Edotreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/lutetium-lu-177-edotreotide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab